SBIR/STTR Research Award

Bioelastic Materials for Strabismus and Retinal Surgery

Award identifier 02553bbccd86afbf234a30cb001f33f2a53d3360a9d375e2cc0c554383f625e0Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1993

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
BIOELASTICS RESEARCH, LTD.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

The objective is to modify a currently available, synthetic polypeptide polymer to prevent the adhesions and fibrovascular scarring which can follow strabismus and retinal detachment surgery. Such scarring often produces significant restriction to eye movement and malposition of the eyes. The polypeptide, which has already been shown to prevent scar formation in a rabbit experimental model, is now formed in sheets and large tubes. The polypeptide will be modified by the inclusion of ester bonds and chemical clocks to facilitate its degradation in the subconjunctival space. Such a material should have significant clinical application, particularly in reoperation procedures for strabismus and retinal detachment surgery involving the extraocular muscles. The project will utilize a new class of unique biomaterials, elastomeric polypeptides, which are polymers constructed of repeating sequences that occur in native elastin. These materials are particularly suited to this application since they are polypeptides of natural amino acids and arranged in sequences that occur throughout the body. All data to date, including eleven recommended generic biological tests, indicate these materials to be biocompatible and totally innocuous. Phase I will focus on the development of an elastomer which degrades at a suitable rate and shows no adverse reaction in the rabbit model. These studies will be extended in Phase II to the biological testing of the materials developed in Phase I, and more extensive animal studies will be designed to move the application toward clinical trials.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.